Peter Gasser, MD
The Development of Psycholytic / Psychedelic Therapy
Research and therapy with mind altering drugs has a tradition in Switzerland. It started with the discovery of LSD in 1943, then the first clinical publication of the use of LSD in 1946, the use of LSD and MDMA in therapy in 1988 until 1993, the important basic scientific work of F. Vollenweider about Psilocybin after the mid 1990ies and regular clinical and therapeutical research since the early 2000ies. The presentation focusses on the development of the therapeutical use, shows the results of the studies done in Switzerland and outlines the further development towards a normalization of therapy with mind altering substances that is legally embedded and based on medical evidence.
Dr. med., born in 1960, married, three children. Physician for psychiatry and psychotherapy, working in private practice in Solothurn, Switzerland. He was trained in psychodynamic methods as well as in therapy with mind altering drugs, i.e. psycholytic or psychedelic therapy. He is member of the Swiss Medical Society for Psycholytic Therapy since 1992 and its president since 1996. From 2008 to 2012 he conducted a randomized controlled trial with LSD assisted treatment in patients suffering from life threatening diseases. A second study with the same study questions is running from 2017 to 2021. In addition to that Peter Gasser holds a number of individual permissions issued by the Swiss Federal Office for Public Health for the treatment with LSD or MDMA (so called compassion-ate use treatments).